Jerry L. Nadler, M.D., MACP, FAHA, FACE
Dean, School of Medicine
Professor of Medicine and Pharmacology
Born and raised in Brooklyn, New York, Dr. Nadler became inspired to find a cure for diabetes when he was ten years old—having witnessed the ways adult onset type-1 diabetes ravaged his uncle’s health. That quest to advance our understanding of diabetes led him to University of Miami’s Miller School of Medicine where he worked with Dr. Daniel Mintz, the founding scientific director and chief academic officer of the Diabetes Research Institute, to the University of Southern California for specialized endocrinology training in research and to the City of Hope Medical Center in Duarte, California, where he built the City of Hope’s Diabetes Program. Additionally, Dr. Nadler was chief of Endocrinology and Metabolism at the University of Virginia, co-director of the Diabetes and Hormone Center of Excellence and associate director of the school’s National Institutes of Health (NIH) funded Diabetes Endocrinology Research Center.
Just prior to coming to New York Medical College, Dr. Nadler served as professor and chair of Internal Medicine, the Harry H. Mansbach Endowed Chair in Internal Medicine and vice dean of Research and director of the Strelitz Diabetes Center (SDC) at Eastern Virginia Medical School (EVMS).
An internationally recognized diabetes researcher, Dr. Nadler has been a member of a Special Advisory Committee on Type I Diabetes with the director of the NIH. In addition, he had been a standing member of the American Diabetes Association, American Heart Association, and NIH grant review committees. In 2011, he won the Dean’s Outstanding Faculty Award at EVMS, and in 2013, he was appointed in 2013 by the Governor’s office of the Commonwealth of Virginia to sit on the Planning and Oversight Committee of the new Virginia Biosciences Health Research Corporation. He was elected to the American Society of Clinical Investigation based on excellence in research.
Dr. Nadler’s groundbreaking contributions—which focus on understanding cardiovascular complications of diabetes and obesity—include his work in identifying inflammatory pathways leading to pancreatic beta cell damage, insulin resistance and atherosclerosis. Toward this end, his research has led to the development of preventative therapies and the identification of new small molecules blocking 12-Lipoxygenase activity. He has research funding from the NIH as well as the Juvenile Diabetes Foundation and his current work is designed to determine whether a virus could be a trigger for Type 1 diabetes.
As a prominent voice in his field, he has authored more than 200 peer-reviewed publications and has been an invited speaker at major international conferences including the American Diabetes Association, Australian Diabetes Association, World Diabetes Congress and International Meetings of the European Association of Diabetes.
Additionally, as a leader in biomedical innovation, Dr. Nadler holds 15 patents for biomarkers and novel therapeutics, and has taken on leadership roles in launching numerous bio-tech startup companies.